Population
Coxsackievirus A6 (CVA6) particles (procapsid and A-particle)
Design
Preclinical
Authors
Loading...
Stable CVA6 particles may advance vaccine development; leaves open clinical immunogenicity and efficacy.
The identification of the CVA6 procapsid and A-particle structures and an immune-dominant neutralizing epitope provides targets for designing anti-CVA6 vaccines.
Xu et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: